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Background. A considerable diversity in prognosis is seen
with lupus glomerulonephritis (LGN). Hence, the clinical use-
fulness of a recent International Society of Nephrology/Renal
Pathology Society (ISN/RPS) 2003 classification to judge the
long-term outcome of human LGN has been investigated.
Methods. We studied retrospectively 60 subjects with LGN
(7 males, 53 females, mean age of 33 years old) who under-
went renal biopsies and were followed from 1 to 366 months,
with a mean of 187 months. We diagnosed renal pathology as
classes, active and sclerosing lesions, according to the new and
WHO1995 classification of LGN, and analyzed the clinicopatho-
logic factors affecting to the prognosis of LGN.
Results. New classification got much higher consensus in the
judgment of classes (98% vs. 83%, P = 0.0084). The group of
Class IV-S (N = 6) or IV-G (N = 17) at initial biopsies showed
higher rate of end-stage renal failure (ESRF) compared with
that of Class I, II, III or V (40.9% vs. 2.6%, P < 0.001). The
mean 50% renal survival time of Class IV was 189 ± 29 months,
and patients with Class IV-S tended to have a poorer progno-
sis (95 ± 22 months for IV-S vs. 214 ± 35 months for IV-G,
P = 0.1495). Class IV was also selected as the most significant
risk factor for ESRF by stepwise model (P = 0.002). In sub-
analysis for ESRF in Class IV (-S or –G), treatment including
methylprednisolone pulse therapy was only selected as a sig-
nificant improving factor for primary outcome (P = 0.034). In
addition, activity index was the significant risk factor of death
and/or ESRF after initial renal biopsies (P = 0.043). As for ac-
tuarial patient death during all follow-up periods, complications
1The centers and investigators participating in this study are listed in
the Appendix.
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with anti-phospholipid syndrome or nephrotic syndrome were
significant risk factors (P = 0.013, P = 0.041, respectively).
Conclusion. New ISN/RPS 2003 classification provided ben-
eficial pathologic information relevant to the long-term renal
outcome and the optimal therapy preventing ESRF and/or
death in patients with LGN.
Systemic lupus erythematosus (SLE) is a multisystem
autoimmune disease with the characteristic development
of autoantibodies to DNA and other nuclear antigens, as
well as to membrane molecules such as phospholipids.
About 20% to 50% of unselected patients with lupus are
reported to have abnormal urine tests in their early dis-
ease courses, and up to 60% of adults may go on to de-
velop overt renal abnormalities. A considerable diversity
in prognosis is seen with lupus nephritis, however. The
glomerular lesions in lupus nephritis are so variable, lead-
ing to a more complex clinical expression of this disease
[1–2].
Concerning the classification of lupus nephritis, the first
1974 World Health Organization (WHO) classification
was examined in 1978 by Appel et al [3]. In 1982, the
1974 WHO classification was modified. This 1982 WHO
classification [4] introduced subdivisions for Class III and
IV based on the presence of active, chronic, or mixed
types of glomerular injury. Austin et al [5] devised a sys-
tem of applying semiquantitative scores for activity and
chronicity by grading and adding the individual morpho-
logic components in a given biopsy as a guide to treat-
ment and prognosis. Activity and chronicity scores have
been used as an adjunct to the WHO classification of lu-
pus nephritis [5, 6]. In 1995, segmental glomerular capil-
lary wall necrosis, a lesion also characteristic of glomeru-
lar injury in systemic vasculitis, was paid much attention
[7]. In this notion, Najafi et al [8] revealed the poor out-
come of lupus glomerulonephritis (LGN) with segmental
necrosis involving over 50% of glomeruli as compared to
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category IV lupus nephritis (diffuse proliferative
glomerulonephritis).
In order to accommodate the clinicopathologic and
pathogenetic insights, a new revised classification was
proposed recently [9]. This revised classification intro-
duced several important modifications concerning quan-
titative and/or qualitative differences between Class III,
IV, and V lesions. Like the preceding classifications,
the new classification is based exclusively on glomeru-
lar pathology and, as such, represents a classification of
LGN.
Hence, we investigated the clinical usefulness of a re-
cent International Society of Nephrology/Renal Pathol-
ogy Society (ISN/RPS) 2003 classification of LGN to
judge the long-term outcome of human LGN in a ret-
rospective study. We found that new ISN/RPS 2003
classification provides beneficial pathologic information
relevant to the renal outcome of LGN.
METHODS
Patients and treatments
We retrospectively enrolled 60 Japanese subjects
(7 males and 53 females, aged 14 to 63 years, mean
33 years) with SLE diagnosed by the adequate evalua-
tions of the 1982 or 1997 American Rheumatism Associ-
ation [10–11], who were admitted to the First Department
of Internal Medicine of Kanazawa University Hospital,
or its affiliated hospitals, between 1973 and 2000. Clini-
cal state on admission was judged as acute nephritic syn-
drome, rapidly progressive nephritic syndrome, recurrent
or persistent hematuria, chronic nephritic syndrome, and
nephrotic syndrome, as shown in clinical syndromes and
glomerular histopathology of WHO classification [4, 7].
We followed these patients for at least 3 years, or until
end-stage renal failure (ESRF) or death since the first
renal biopsies (from 1 to 366 months, mean 187 months).
Diagnosis of LGN was confirmed in all patients by per-
cutaneous needle renal biopsy. We also did renal biopsies
in 6 patients at clinical relapse of nephritis, and in 22 pa-
tients as follow-up biopsies to judge the disease activities.
The patients were treated nonrandomly depending on the
judgment of the doctors in charge of each case, with either
no immunosuppressant or supportive therapy (N = 2),
oral corticosteroid (steroid) (prednisolone 20-60 mg/day,
N = 58), including intravenous methylprednisolone pulse
therapy (500-1000 mg/day × 3 days, 1–3 times, N = 35),
steroid with oral immunosuppressants such as cyclophos-
phamide, azathioprine, mizoribine, or cyclosporine (N =
17), or high-dose intravenous cyclophosphamide (10 mg/
kg/2–4 weeks, 2–4 times), followed by oral immunosup-
pressants (N = 4). Informed consent was obtained for
all renal biopsies and treatments. Anti-phospholipid an-
tibody syndrome (APS) was diagnosed according to the
1989 criteria of Harris and Hughes [12], or the 1999 Sap-
poro criteria [13].
Histopathologic studies
Light microscopic examination. For light microscopic
examination (LM), renal biopsy specimens were fixed in
10% phosphate-buffered formalin (pH 7.4), embedded
in paraffin, and sliced into 4-lm sections. These speci-
mens were stained with hematoxylin and eosin, periodic
acid Schiff reagent, Mallory-azan, and periodic acid silver
methenamine, and were examined by light microscopy,
with the criteria of the new WHO classification. In brief,
Class I, minimal mesangial LGN; Class II, mesangial pro-
liferative LGN, showing purely mesangial hypercellular-
ity of any degree and/or mesangial matrix expansion;
Class III, focal LGN involving <50% of the total number
of glomeruli; Class IV, diffuse segmental or global LGN
involving 50% or more of the total number of glomeruli
either segmentally or globally. According to the new clas-
sification, Class IV is divided into diffuse segmental (IV-
S), when >50% of the involved glomeruli have segmental
lesions, and diffuse global (IV-G), when >50% of the in-
volved glomeruli have global lesions. Class V is membra-
nous LGN. Class VI is advanced sclerotic LGN with more
than 90% of glomeruli globally sclerosed without residual
activity. The frequency of active and chronic lesions was
determined, and the “activity index (AI)” and “chronic-
ity index (CI)” of the histologic appearance were also
calculated according to the National Institutes of Health
scores by Austin et al [5]. We also classified all biopsied
specimens according to the 1995 WHO classification [7].
Renal tissue specimens were examined by two patholo-
gists with no knowledge of the patients’ clinical condition
to establish the diagnosis by standard pathologic methods
alone.
Immunofluorescent examination. Fresh specimens ob-
tained from needle biopsies were embedded in OCT
compound, snap frozen in n-hexane cooled with a mix-
ture of dry ice and acetone, and cut into 6-lm sections
on a cryostat (Tissue-Tek II systems; Miles, Naperville,
IL, USA). Sections were treated with fluorescein isothio-
cyanate (FITC)-labeled antihuman immunoglobulin (Ig)
G (c-chain), IgA (a-chain), and IgM (l-chain) sheep
IgG/F (ab’) 2 antibodies, and FITC-labeled antihuman
C3 and C1q sheep IgG antibodies (Cappel, West Chester,
PA, USA) for immunofluorescent studies.
Electron microscopic examination. A part of biopsied
specimens was fixed with glutaraldehyde and osmium
tetroxide, embedded in Epon 812 (Oken Shoji Co., Tokyo,
Japan), sliced into 0.1-lm sections, double-stained with
uranyl acetate and lead citrate, and examined under the
electron microscope (Hitachi H-600, Hitachi Co., Tokyo,
Japan). For this study, specimens were examined with em-
phasis on subendothelial, subepithelial, and intramem-
branous electron dense deposits.
2384 Yokoyama et al: Outcome in a new classification of LGN
.8
1
.6
.4
.2
0
R
en
al
 s
ur
vi
va
l r
a
te
0 50 10
0
15
0
20
0
25
0
30
0
Follow-up period, months
P = 0.006
Nephrotic (N = 21)
Non-nephrotic (N = 39).8
1
.6
.4
.2
0
Su
rv
iva
l r
a
te
0 50 10
0
15
0
20
0
25
0
30
0
Secondary (N = 60)
Primary (N = 60)
Follow-up period, months
A B
Fig. 1. The primary and secondary outcomes
of the retrospective analysis of 60 Japanese
subjects with lupus glomerulonephritis since
1973. Primary and secondary outcomes of all
subjects were 82% and 78% at 10 years, and
80% and 73% at 20 years, respectively (A).
Primary outcome of subjects with nephrotic
syndrome (N = 21) was significantly poor
as compared to that of subjects without
nephrotic syndrome (N = 39) (B). The mean
time of 50% renal survival in subjects with
nephrotic syndrome was 200 ± 29 months
(P = 0.0007 by the Kaplan and Meier life-table
method).
Clinical evaluation
Baseline clinical data were extracted from hospital
records. They included values of serum creatinine, serum
albumin, 24-hour urine protein excretion, serum levels
of complements (C3, C4, CH50), and anti-phospholipid
antibodies or lupus anticoagulants.
Clinical status was assessed according to Japanese clin-
ical categories employing the criteria of nephrotic state,
presence of marked proteinuria greater than 3.5 g/day or
3+ (300 mg/dL) to 4+ (1000 mg/dL) by Multistics (Miles),
and hypoalbuminemia (less than 30 g/L). Renal dysfunc-
tion was defined as a serum creatinine level of greater
than 132.6 lmol/L (1.5 mg/dL), or an endogenous creati-
nine clearance of less than 60 mL/min. ESRF was defined
as the need for hemodialysis, peritoneal dialysis, or renal
transplantation. Primary outcome was defined as ESRF,
and secondary outcome as patients’ death and/or ESRF.
Statistical analysis
Statistical analyses were performed using Kruskal-
Wallis nonparametric analysis of variance test and
Wilcoxon rank-sum test for continuous data, and Fisher
exact test for categorical data, the Mantel-Cox log-rank
test, and the Kaplan and Meier life-table method for renal
or patients’ survival. The independent risk factors for pri-
mary and secondary outcomes were performed with the
Cox proportional hazards model. Values were expressed
as mean ± standard error of mean (SEM). P values of less
than 0.05 were considered statistically significant. SAS
software (Cary, NC, USA) was used for the statistical
calculation [14].
RESULTS
Clinical findings and outcomes of lupus
glomerulonephritis
Twenty-one patients (35%) were diagnosed as
nephrotic syndrome on admission, two (3.3%) as acute
nephritic syndrome, and two (3.3%) as rapidly progres-
sive nephritic syndrome according to the WHO criteria.
Thirty-five other patients showed urinary abnormality,
such as microscopic hematuria and/or proteinuria. Pri-
mary and secondary outcomes of all patients were 82%
and 78% at 10 years, and 80% and 73% at 20 years, re-
spectively (Fig. 1A). One patient with rapidly progres-
sive nephritic syndrome died of pulmonary infection at
onset. Another patient of rapidly progressive nephritic
syndrome reached ESRF after 86 months, but survived
with hemodialysis for 21 years from the initial diagnosis
at 1983. Two patients with acute nephritic syndrome had
Class IV-G (A) LGN with diffuse endocapillary prolif-
eration at onset, and entered remission by immunosup-
pressive therapies. Primary outcome of nephrotic syn-
drome (N = 21) was significantly poor compared to pa-
tients without nephrotic syndrome (N = 39). The mean
50% renal survival time of nephrotic patients was 200 ±
29 months (P =0.0007, Fig. 1B). Finally, 10 patients (17%)
reached ESRF from 24 to 278 months after the first re-
nal biopsy. Then, 10 patients in ESRF were treated by
hemodialysis in 9 patients and renal transplantation in
one patient. Six patients died during hemodialysis ther-
apy because of vascular events in 3 patients with APS, and
infectious diseases in 3 other patients with lupus activity.
Clinicopathologic findings at the initial renal biopsy and
alterations of lupus glomerulonephritis
At initial renal biopsies, 9 patients showed Class I, 10
in Class II, 8 in Class III with 6 of III (A), and 2 of III
(A/C). Twenty-three patients were judged as Class IV,
including 17 in Class IV-G with 2 of IV-G (A) and 15
of IV-G (A/C), 6 in Class IV-S with one of IV-S (A)
and 5 of IV-S (A/C). Both Class IV-S and Class IV-G
showed higher scores of activity and chronicity indices
(P < 0.0001 for AI, P = 0.0004 for CI). Ten patients show-
ing mainly subepithelial or intramembranous dense de-
posits were diagnosed as Class V. There was no Class VI in
our series at the initial renal biopsy. When we compared
the pathologic diagnoses between two pathologists using
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Table 1. Profiles of patients at initial renal biopsies
ISN/RPS 2003 AI/CI
classification NO. Age years Sex F:M u-Prot g/day s-Alb g/dL NS s-Cr mg/dL CH50 U/mL mean score
Class I 9 34 ± 6 9:0 0.2 ± 0.1 4.4 ± 0.2 0 (0%) 0.7 ± 0.1 29 ± 2 0.2/0.2
Class II 10 30 ± 4 9:1 0.2 ± 0.1 4.2 ± 0.2 0 (0%) 0.7 ± 0.1 26 ± 3 0.5/0.1
Class III 8 35 ± 6 6:2 1.5 ± 0.4 3.6 ± 0.2 1 (13%) 0.7 ± 0.2 24 ± 4 4.5/0.5
A (6), A/C (2)
Class IV-S 6 31 ± 7 5:1 3.9 ± 1.1 3.2 ± 0.4 4 (67%) 1.3 ± 0.2 22 ± 6 5.3/2.0
A (1), A/C (5)
Class IV-G 17 36 ± 2 14:3 3.7 ± 0.5 3.0 ± 0.2 10 (59%) 1.3 ± 0.2 18 ± 3 6.6/3.3
A (2), A/C (15)
Class V 10 32 ± 4 10:0 3.6 ± 0.7 2.8 ± 0.3 6 (60%) 0.7 ± 0.1 24 ± 2 0.3/0.5
Total 60 33 ± 2 53:7 2.3 ± 0.3 3.5 ± 0.1 21 (35%) 0.9 ± 0.1 23 ± 1 3.2/1.4
Abbreviations are: u-Prot, urinary protein; s-Alb, serum albumin levels; NS, nephrotic syndrome; s-Cr, serum creatinine levels; AI/CI, activity index/chronicity index.
Table 2. Alteration of renal pathology and clinical outcomes
ISN/RPS 2003 Remission/NS ESRF/prolonged
classification Initial no. or ESRFa Relapse/rebiopsy Final no. NS
Class I 9 9 (100%)/0 (0%) 1 relapse → V 8 0 (0%)/0 (0%)
8 no rebiopsy
Class II 10 10 (100%)/0 (0%) 1 relapse → V 10 0 (0%)/0 (0%)
9 no rebiopsy
Class III 8 8 (100%)/0 (0%) 1 relapse → V 7 0 (0%)/0 (0%)
(A) 6, (A/C) 2 1 follow-up III(A)→III(C)
6 no rebiopsy
Class IV-S 6 2 (33%)/4 (4a, 67%) 1 relapse → IV-G(A/C) 3 1 (33%)/0 (0%)
(A/C) 5, (C) 1 4 follow-up →IV-S(A/C)1,-S(C)1; IV-G(A/C) 1, -G(C) 1
1 no rebiopsy
Class IV-G 17 11 (65%)/6 (5a, 29%) 1 relapse → V 18 8 (44%)/1 (6%)
(A) 2, (A/C) 15 13 follow-up →II 1, IV-G(A/C)11, IV-G(C) 1
3 no rebiopsy
Class V 10 7 (70%)/3 (1a, 10%) 1 relapse → V+IV-G(A/C)b 14 1b (7%)/2 (14%)
+II 2, +III(A) 2 4 follow-up → V 3, V+III (A/C) 1
5 no rebiopsy
Total 60 47 (78%)/13(10a, 17%) 6 rebiopsies at relapse 60 10 (17%)/3 (5%)
22 follow-up biopsies
NS, nephrotic syndrome; ESRF, end-stage renal failure.
aCases with ESRF.
bA case of class V + IV-G reached ESRF.
WHO1995 classification and new ISN/RPS2003 classifi-
cation, there were some discrepancies in class judgments
in 10 specimens (17%) by WHO1995 classification, and
one specimen (2%) by ISN/RPS2003 classification (P =
0.0084 by Fisher exact test).
Patients with Class IV-S, IV-G, or V had massive pro-
teinuria with lower serum albumin levels than those of
patients with Class I, II, or III (P < 0.001 for proteinuria,
P = 0.003 for serum albumin). Serum creatinine levels
were much higher in patients with Class IV-G or IV-S
(P < 0.005). Patients with Class IV, especially Class IV-
G, also tended to have lower serum complement (CH50)
levels (P = 0.07, Table 1).
Eight patients changed their histologic classes during
follow-up periods. Four patients showing clinical relapse
or worsening of proteinuria (each one of Class I, II, III,
and IV-G) were diagnosed as Class V at the episodic
renal biopsies. Two patients initially diagnosed as Class
IV-S (A/C) changed to Class IV-G (A/C) or -G(C) by
the follow-up biopsies after 3 to 36 months. One pa-
tient, changed from Class V (pure membranous) to Class
V+IV-G (A/C), also reached ESRF and died of severe
thrombocytopenia and pulmonary infection during her
dialysis therapy (Table 2).
There was a significant difference in primary outcome
between patients with Class I, II, III, or V, and patients
with Class IV-S or IV-G (N = 23) at initial biopsy findings
(Fig. 2A). Patients with Class IV-S or IV-G at final biop-
sies showed higher rate of ESRF compared with that of
Class I, II, III, or V (40.9% vs. 2.6%, P < 0.001, Table 2).
The mean 50% renal survival time of Class IV was 189
± 29 months (P < 0.0001 by the Kaplan and Meier life-
table method, Fig. 2A). Patients with Class IV-S showed
much higher rate of ESRF in 4 out of 6 (67%). There was
no statistic difference in primary outcome between Class
IV-S and IV-G of initial pathologic diagnosis by the Ka-
plan and Meier life-table method, however. Patients with
Class IV-S tended to have a poorer prognosis (the mean
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Fig. 2. Different primary outcome of pa-
tients with LGN by initial pathologic findings.
The group of Class IV-S or IV-G at initial biop-
sies showed higher rate of ESRF as compared
with that of Class I, II, III, or V (40.9% vs.
2.6%) (A). The mean time of 50% renal sur-
vival in subjects with Class IV-S or -G was 189
± 29 months (P < 0.0001 by the Kaplan and
Meier life-table method). There was no statis-
tic difference in primary outcome between
Class IV-S and IV-G, however (B). The mean
times of 50% renal survival in subjects with
Class IV-S and -G were 95 ± 22 months and
214 ± 35 months, respectively.
Table 3. Clinicopathologic factors for primary outcome
Multivariate Cox hazard analysis
Hazard ratio 95% CI P value
LGN class IV-S or G 14.82 1.42–155.3 0.025
Nephrotic state (+) 3.39 0.61–18.87 0.163
Activity index 1.10 0.86–1.40 0.437
APS (+) 1.09 0.25–4.65 0.910
Age 0.95 0.88–1.03 0.192
Chronicity index 0.93 0.62–1.40 0.709
Multivariate stepwise Cox hazard analysis
Hazard ratio chi-square P value
LGN class IV-S or G 25.55 9.42 0.0021
CI, confidence interval, APS, anti-phospholipid syndrome.
time of 50% renal survival, 95 ± 22 months for IV-S vs.
214 ± 35 months for IV-G, P = 0.1495, Fig. 2B).
Clinicopathologic factors for primary and secondary
outcomes and patients’ survival
In multivariate Cox hazard analysis of the clinicopatho-
logic factors, Class IV (-G or -S) was selected as the
most significant risk factor for ESRF by stepwise model
(Table 3). In subanalysis for ESRF in Class IV (-S or
-G), treatment including methylprednisolone pulse ther-
apy was only selected as a significant improving factor for
primary outcome (hazard ratio 5.507, 95% confidence in-
terval 1.128–26.891, P = 0.0349). When we did the same
analyses by changing the Class IV judgment from new
ISN/RPS2003 classification to WHO1995 classification,
Class IV was not selected as a risk factor for primary
outcome (hazard ratio 2.162, 95% CI 0.146–31.914, P =
0.5745), but nephrotic state was significant (hazard ratio
7.353, 95% CI 1.059–50.0, P = 0.043).
As for secondary outcome, activity index was the sig-
nificant risk factor after initial renal biopsies (Table 4). In
addition, treatment and proteinuria before therapy were
selected as risk factors for secondary outcome in Class IV
(-S or -G) (hazard ratio 5.476, 95% CI 1.248–24.019, P =
0.0242 for treatment; 13.153, 1.077–160.556, P = 0.0435
Table 4. Clinicopathologic factors for secondary outcome
Multivariate Cox hazard analysis
Hazard ratio 95% CI P value
Nephrotic state (+) 4.03 0.99–16.39 0.051
LGN class IV-S or G 2.15 0.60–7.70 0.241
APS (+) 2.49 0.73–8.49 0.144
Activity index 1.20 1.01–1.44 0.043
Age 0.98 0.92–1.04 0.563
Chronicity index 0.91 0.66–1.25 0.559
Table 5. Clinicopathologic factors for patients’ survival
Multivariate Cox hazard analysis
Hazard ratio 95% CI P value
APS(+) 10.87 1.84–63.97 0.0083
LGN class IV-s or G 5.31 0.79–35.74 0.0856
Nephrotic state (+) 3.85 0.60–24.39 0.1555
Activity index 1.28 0.98–1.66 0.0644
Age 1.00 0.92–1.08 0.9680
Chronicity index 0.57 0.33–0.99 0.0495
Multivariate stepwise Cox hazard analysis
Hazard ratio chi-square P value
APS (+) 5.29 6.07 0.0138
Nephrotic state (+) 3.85 4.14 0.0418
for proteinuria). Then, as for patients’ survival during all
follow-up periods, complications with APS or nephrotic
syndrome were significant risk factors (P = 0.0138, P =
0.0418, respectively, Table 5). In this study, 13 patients
were diagnosed as APS. Four patients of APS died of
arterial thrombosis, 3 hemodialysis patients and in one
patient without ESRF. The mean time of 50% survival in
patients with APS and LGN was 164 ± 12 months.
DISCUSSION
In order to accommodate the clinicopathologic in-
sights, a new revised classification of LGN was pro-
posed recently [9]. This new classification introduced
several important modifications concerning quantitative
and/or qualitative difference between Class III, IV, and V
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lesions. We have investigated the clinical usefulness of this
ISN/RPS 2003 classification to judge the long-term out-
come of human LGN in a retrospective study of Japanese.
There were some major discussion points in old 1992
and 1995 WHO classification that there is any difference
in the quantitative distribution of segmental lesions be-
tween <50%, and more than 50% or not. In other words,
some cases with segmental necrosis in more than 50%
of glomeruli (category III more than 50%, focal and
segmental glomerulonephritis) showed poor prognosis
compared to cases with diffuse global endocapillary hy-
percellularity without necrosis (category IV, diffuse pro-
liferative glomerulonephritis), as reported by Najafi et al
[8]. This issue was clearly resolved in the new classifica-
tion that such cases with severe segmental lesions more
than 50% of glomeruli were classed as IV-S. In our anal-
ysis, new ISN/RPS 2003 classification was much easier
for diagnosis of LGN with little discrepancy in the judg-
ment of classes. Hence, there was a significant difference
between new Class III and new Class IV, including both
Class IV-G and IV–S. In addition, new Class IV judgment
was selected as a significant risk factor for the primary
outcome, but not category IV of old WHO 1995 classi-
fication. These findings indicated that the new ISN/RPS
2003 classification provided useful information relevant
to the long-term renal outcome of human LGN.
As for concern to the difference between Class IV-
S (segmental lesions) and Class IV-G (diffuse lesions),
there was no statistic difference in renal outcome in this
study, suggesting that quantitative (<50% or more than
50%) factor may be important to define the renal out-
come. However, the mean time of 50% renal survival
in Class IV-S, including focal segmental necrotizing le-
sions, tended to be shorter than that of Class IV-G. Pre-
vious reports pointed out that the focal and segmental
glomerular lesions of LGN were characterized by seg-
mental endocapillary proliferation, fibrin deposition, and
an intense inflammatory lesion with karyorrhexis, cell
wall destruction, and crescents. Moreover, such segmen-
tal lesions showing necrosis were similar to the lesions
of systemic vasculitis, suggesting a role of cellular im-
munity in the pathologic process [8, 15]. In addition to
quantitative (<50% or more than 50%) factor, qualita-
tive changes (segmental lesions including necrosis) may
be an important factor for the renal outcome of human
LGN in concern of therapeutic strategies. In the future,
a large prospective study may be required to clarify this
issue of segmental necrotizing lesions in human LGN.
Another question is how do we deal with or judge the
cases of Class V combined with other lesions, or trans-
formed from Class V to other classes such as Class IV. In
1996, Sloan et al [16] reported that membranous glomeru-
lonephritis in patients with SLE (Class Va, pure mem-
branous; Vb, with mesangial hypercellularity; Vc, with
segmental endocapillary proliferation and/or necrosis;
and Vd with superimposed diffuse endocapillary prolif-
eration in 1982 WHO classification) has a heterogeneous
course and outcome, that is, the 10-year actuarial sur-
vival rates of Va and b, Vc<50% or Vc more than 50%,
and Vd were 72%, 48%, and 20%, respectively, and the
differences between these three groups were significant
(P < 0.05). They concluded that this variability was re-
lated to the extent and degree of glomerulonephritis seen
on biopsy. Even in our small group analysis, only one
out of 10 patients (10%) with Class V at initial renal
biopsy reached ESRF because of histologic changes from
pure Class V to Class V+ IV-G (A/C). Three other pa-
tients with Class V showing prolonged nephrotic state
or massive proteinuria over 3 g/day without renal dys-
function had mainly subepithelial or intramembranous
lesions even in the follow-up biopsies after 5 to 10 years.
All 4 patients of Class V combined with Class II or III en-
tered remission by immunosuppressive therapies. These
observations suggested that the renal outcome of Class V
was defined by the complicated lesions, especially Class
IV-G or IV-S lesions, in spite of membranous lesion it-
self. Hence, new classification in a combined designation
of classes may provide useful pathologic information rel-
evant to clinical treatment and the long-term renal out-
come of LGN with Class V.
In multivariate analyses, Class IV-G or -S was only se-
lected as a significant risk factor for primary (renal) out-
come, but not activity index or chronicity index. As for
activity and chronicity scores, because Austin et al de-
vised a system of applying semiquantitative scores for
activity and chronicity by grading and adding the individ-
ual morphologic components in a given biopsy as a guide
to treatment and prognosis, these scores were used as
an adjunct to the WHO classification by many practicing
pathologists and clinicians [5–6, 17]. The reproducibility
and the predictability of these indices have been ques-
tioned by some reports, however [18]. Activity index was
a significant risk factor for secondary outcome (patient
death and/or ESRF) in our analysis. As we previously re-
ported, activity index related positively with circulating
gamma-interferon levels and the degree of glomerular
aberrant MHC class II (HLA-DQ) expression [6], and
elevated urinary interleukin-8 levels [17]. We speculated
that activity index might be reflecting the severity of gen-
eral condition, especially immunologic disease activities
in patients with SLE. Then, the activity index is also a
useful clinicopathologic guide to patients’ treatment of
LGN.
Recently, complication with APS was paid much atten-
tion from not only pathologic findings in renal biopsy [19,
20], but also from clinical treatments [21, 22]. As Daugas
et al [20] reported, the renal involvement attributing to
APS is an independent risk factor over and above LGN
that contributes to an elevated prevalence of hyperten-
sion, elevated serum creatinine levels, and increased in-
terstitial fibrosis. In this study, APS, as well as nephrotic
state, is an independent risk factor for actuarial death
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in patients with LGN. Nephrotic syndrome was mainly
associated with Class IV (both IV-G and IV-S) or pro-
longed Class V. Then, these patients with severe prolif-
erative LGN were treated with initial intensive immuno-
suppressive therapies, followed by maintenance therapy
for remission [23, 24], because the initial intensive ther-
apy including methylprednisolone pulse therapy was only
a preventing factor to ESRF, as shown in the analysis of
Class IV-S or -G in this study. Hence, these therapies in-
creased the incidence of infection in patients with SLE, as
we previously reported [25]. These results suggested that
the optimal therapy being well balanced between disease
activity control, and the advertous effects of immunosup-
pressive therapy should be considered in the treatment
of patients with Class IV or Class V of LGN.
CONCLUSION
We retrospectively analyzed 60 subjects with biopsy
proven LGN, and found that new ISN/RPS 2003 clas-
sification provided beneficial pathologic information
relevant to the long-term renal outcome of LGN and
the optimal therapy preventing ESRF and/or death in
patients with LGN.
APPENDIX
The Kanazawa Renal Study Group: S. Takeda, M.D. (Kurobe Mu-
nicipal Hospital), K. Ikeda, M.D. and M. Shimizu, M.D. (Kouseiren
Takaoka Hospital), S. Goshima, M.D. (Public Inami Hospital), M.
Takaeda, M.D. (Toyama Rosai Hospital), T. Naito, M.D. and H. Iida,
M.D. (Toyama Prefectural Central Hospital), Y. Ishida, M.D. and S.
Ohta, M.D. (Toyama Municipal Hospital), S. Sato, M.D. (Tonami City
Hospital), T. Misaki, M.D. (Public Ushutsu General Hospital), H.
Takakuwa, M.D. and T. Abe, M.D. (Kanazawa Municipal Hospital),
M. Yoshimura, M.D. and H. Kida, M.D. (National Kanazawa Medi-
cal Center), K. Takasawa, M.D. and C. Segawa-Takaeda, M.D. (Public
Matto-Ishikawa Central Hospital), M. Takaeda, M.D. (Neagari Hospi-
tal), T. Kato, M.D. and Y. Ushiogi, M.D. (Fukui Saiseikai Hospital).
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